Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases

• DOI: 10.1111/hpb.12089
• Publication Date: 2013-03-24T09:13:54Z
• Authors: Arpad Ivanecz; Rajko Kavalar; Miroslav Palfy; Vid Pivec; Marko Sremec; Matjaž Horvat; Stojan Potrč
• Keywords: Adult; Male; Chi-Square Distribution; Hepatology; Liver Neoplasms; Gastroenterology; Kaplan-Meier Estimate; Middle Aged; Immunohistochemistry; Risk Assessment; Disease-Free Survival; Decision Support Techniques; 03 medical and health sciences; Ki-67 Antigen; 0302 clinical medicine; Predictive Value of Tests; Multivariate Analysis; Hepatectomy; Humans; Female; Colorectal Neoplasms; Aged; Proportional Hazards Models; Retrospective Studies

The aim of this study was to assess whether biological markers can provide prognostic information additional to that supplied by the clinical risk score (CRS) in patients with colorectal liver metastases.A retrospective review of a prospectively maintained database was conducted. Patients selected for this study were treated between 1996 and 2011 with potentially curative liver surgery. Expressions of p53, Ki-67 and thymidylate synthase were assayed using immunohistochemical techniques on tissue microarrays.A total of 98 (24%) of 406 patients met the inclusion criteria. The median follow-up was 103 months. Analysis revealed a correlation between p53 protein overexpression and high CRS (P = 0.058). Following multivariate analysis, only high CRS remained as an independent negative prognostic predictor of survival (P = 0.018), as well as an indicator of early recurrence of disease (P = 0.010). Of the biological markers investigated, only Ki-67 overexpression was identified as a positive predictor of survival on multivariate analysis (P = 0.038).Ki-67 overexpression was a positive predictor of survival. Only high CRS remained an independent negative prognostic predictor.